ERBB2 and breast cancer: The recent introduction of immunotherapy as a treatment strategy in BC has so far involved only triple-negative (HR negative, HER2 negative) tumors, characterized by increased immune activation and by a higher presence of tumor infiltrating lymphocytes in the tumor stroma (sTIL) [3].